Andrew Dunn
@andrewedunn.bsky.social
Reporter @ Endpoints News
Covering biotech, pharma, AI, and more — the future of medicine
[email protected]
Covering biotech, pharma, AI, and more — the future of medicine
[email protected]
Exclusive: 33-year-old first-time CEO Michelle Lee is officially launching her AI robotics startup Medra
Lee told me Medra has raised $11 million in pre-seed and seed rounds and have landed their first customers: endpoints.news/exclusive-ro...
Lee told me Medra has raised $11 million in pre-seed and seed rounds and have landed their first customers: endpoints.news/exclusive-ro...
Exclusive: A first-time CEO launches startup to bring AI into the lab
Michelle Lee's startup Medra raises $11M to build AI-powered lab robots, attracting Genentech and others as customers. The Stanford PhD aims to automate 70% of lab instruments with flexible robotic sy...
endpoints.news
September 11, 2025 at 12:38 PM
Exclusive: 33-year-old first-time CEO Michelle Lee is officially launching her AI robotics startup Medra
Lee told me Medra has raised $11 million in pre-seed and seed rounds and have landed their first customers: endpoints.news/exclusive-ro...
Lee told me Medra has raised $11 million in pre-seed and seed rounds and have landed their first customers: endpoints.news/exclusive-ro...
So, Eli Lilly has launched TuneLab. What's next?
Mark your calendars for our AI Day on Oct. 14. Our free + virtual sessions include Aliza Apple, TuneLab's leader at Lilly.
Sign up here in <10 secs for free access to livestreams & on-demand recordings: events.endpoints.news/aiday2025/re...
Mark your calendars for our AI Day on Oct. 14. Our free + virtual sessions include Aliza Apple, TuneLab's leader at Lilly.
Sign up here in <10 secs for free access to livestreams & on-demand recordings: events.endpoints.news/aiday2025/re...
AI Day 2025
Biopharma’s relationship with AI is reaching a tipping point. While Big Pharma doubles down on AI to streamline development, a wave of startups is betting the tech can overhaul R&D from the ground up....
events.endpoints.news
September 10, 2025 at 3:04 PM
So, Eli Lilly has launched TuneLab. What's next?
Mark your calendars for our AI Day on Oct. 14. Our free + virtual sessions include Aliza Apple, TuneLab's leader at Lilly.
Sign up here in <10 secs for free access to livestreams & on-demand recordings: events.endpoints.news/aiday2025/re...
Mark your calendars for our AI Day on Oct. 14. Our free + virtual sessions include Aliza Apple, TuneLab's leader at Lilly.
Sign up here in <10 secs for free access to livestreams & on-demand recordings: events.endpoints.news/aiday2025/re...
NEW: Eli Lilly, the world's most valuable drugmaker, is offering biotechs free access to a suite of its own AI models for R&D.
My latest dives into TuneLab's unique setup and initial focus on small molecule ADMET and antibody developability:
endpoints.news/eli-lilly-of...
My latest dives into TuneLab's unique setup and initial focus on small molecule ADMET and antibody developability:
endpoints.news/eli-lilly-of...
In first-of-its-kind setup, Lilly offers startups free access to its AI models in exchange for data
Eli Lilly is offering an unusual deal to any biotech: contribute some data, and in exchange, get access to many of Lilly's own AI models. The initiative, called TuneLab, debuted ...
endpoints.news
September 9, 2025 at 12:18 PM
NEW: Eli Lilly, the world's most valuable drugmaker, is offering biotechs free access to a suite of its own AI models for R&D.
My latest dives into TuneLab's unique setup and initial focus on small molecule ADMET and antibody developability:
endpoints.news/eli-lilly-of...
My latest dives into TuneLab's unique setup and initial focus on small molecule ADMET and antibody developability:
endpoints.news/eli-lilly-of...
Exclusive: Asa Abeliovich's Leal Therapeutics has closed a $30M Series A, funding its two lead drug candidates for schizophrenia and ALS trials
More here — including a surprising obesity angle to its lead compound: endpoints.news/neuro-biotec...
More here — including a surprising obesity angle to its lead compound: endpoints.news/neuro-biotec...
Exclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials
Leal Therapeutics raises Series A funding led by SV Health Investors for neurology drugs LTX-001 and LTX-002. CEO Asa Abeliovich plans clinical trials through 2026.
endpoints.news
August 26, 2025 at 12:10 PM
Exclusive: Asa Abeliovich's Leal Therapeutics has closed a $30M Series A, funding its two lead drug candidates for schizophrenia and ALS trials
More here — including a surprising obesity angle to its lead compound: endpoints.news/neuro-biotec...
More here — including a surprising obesity angle to its lead compound: endpoints.news/neuro-biotec...
Exclusive: I talked with leaders of OpenAI and Retro Bio about new lab results from an AI protein model called GPT-4b micro.
While the model won't be released publicly, the research shows how LLMs could be applied to life sciences research:
endpoints.news/openai-retro...
While the model won't be released publicly, the research shows how LLMs could be applied to life sciences research:
endpoints.news/openai-retro...
Exclusive: OpenAI, Retro Bio detail lab results with AI protein model, plan use in drug program
OpenAI and Retro Biosciences report AI-made proteins showed 50x better cell reprogramming using modified Yamanaka factors, with potential therapeutic applications
endpoints.news
August 22, 2025 at 3:05 PM
Exclusive: I talked with leaders of OpenAI and Retro Bio about new lab results from an AI protein model called GPT-4b micro.
While the model won't be released publicly, the research shows how LLMs could be applied to life sciences research:
endpoints.news/openai-retro...
While the model won't be released publicly, the research shows how LLMs could be applied to life sciences research:
endpoints.news/openai-retro...
Exclusive: Formation Bio raised a $372M Series D last year.
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Exclusive: Formation licenses first drug since $372M raise, eyes more deals in 2025
Formation Bio licenses first-in-class anti-CD226 antibody from IMIDomics for IBD treatment, marking first drug acquisition since $372M Series D raise in 2023.
endpoints.news
July 29, 2025 at 12:20 PM
Exclusive: Formation Bio raised a $372M Series D last year.
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
Later today, the New York biopharma will announce its first licensing deal since raising that money — bringing in a CD226 antibody from the Spanish biotech IMIDomics.
My latest for @endpts.com: endpoints.news/exclusive-fo...
NEW: RevMed will pair its unique library of molecular structures and data with the AI models developed by Iambic Therapeutics, the two biotechs announced Wednesday.
Revolution to pay $25 million in short term to Iambic through upfront + near-term milestones:
endpoints.news/revolution-a...
Revolution to pay $25 million in short term to Iambic through upfront + near-term milestones:
endpoints.news/revolution-a...
Revolution and Iambic to combine data and AI models in R&D deal for cancer drugs
Revolution Medicines has become one of the industry's most valuable pre-commercial companies thanks to its pipeline of clinical-stage cancer drugs. CEO Mark Goldsmith is pressing ahead on ...
endpoints.news
July 9, 2025 at 12:09 PM
NEW: RevMed will pair its unique library of molecular structures and data with the AI models developed by Iambic Therapeutics, the two biotechs announced Wednesday.
Revolution to pay $25 million in short term to Iambic through upfront + near-term milestones:
endpoints.news/revolution-a...
Revolution to pay $25 million in short term to Iambic through upfront + near-term milestones:
endpoints.news/revolution-a...
This has turned into an annual summer tradition of mine — analyzing compensation trends across the biopharma world
In today's story, I analyzed 475 CEO pay packages, finding the 20 highest-paid for 2024:
endpoints.news/the-highest-...
In today's story, I analyzed 475 CEO pay packages, finding the 20 highest-paid for 2024:
endpoints.news/the-highest-...
Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays
Biopharma CEO median pay hit $4.73M in 2024, up 40%. 20 CEOs made over $20M, including Pfizer's Bourla, Vertex's Kewalramani, Amgen's Bradway & Royalty Pharma's Legorreta.
endpoints.news
July 8, 2025 at 3:24 PM
This has turned into an annual summer tradition of mine — analyzing compensation trends across the biopharma world
In today's story, I analyzed 475 CEO pay packages, finding the 20 highest-paid for 2024:
endpoints.news/the-highest-...
In today's story, I analyzed 475 CEO pay packages, finding the 20 highest-paid for 2024:
endpoints.news/the-highest-...
NEW: I interviewed KalVista CEO Ben Palleiko on the heels of its FDA approval for an HAE drug.
"We were fairly blindsided by when your report came out, because until then, we hadn’t had the slightest idea.”
More here in my latest for @endpts.com
endpoints.news/kalvista-ceo...
"We were fairly blindsided by when your report came out, because until then, we hadn’t had the slightest idea.”
More here in my latest for @endpts.com
endpoints.news/kalvista-ceo...
KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask
The company felt 'fairly blindsided' upon reading the report that FDA Commissioner Marty Makary had briefly yet unsuccessfully tried to intervene in the review of its newly-approved HAE drug.
endpoints.news
July 7, 2025 at 6:21 PM
NEW: I interviewed KalVista CEO Ben Palleiko on the heels of its FDA approval for an HAE drug.
"We were fairly blindsided by when your report came out, because until then, we hadn’t had the slightest idea.”
More here in my latest for @endpts.com
endpoints.news/kalvista-ceo...
"We were fairly blindsided by when your report came out, because until then, we hadn’t had the slightest idea.”
More here in my latest for @endpts.com
endpoints.news/kalvista-ceo...
Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene
endpoints.news/fda-approves...
endpoints.news/fda-approves...
Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene
FDA approves KalVista Pharmaceuticals' sebetralstat for hereditary angioedema after controversy involving FDA Commissioner Makary's attempted intervention in review process
endpoints.news
July 7, 2025 at 12:01 PM
Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene
endpoints.news/fda-approves...
endpoints.news/fda-approves...
NEW: An inside look at the growing divide among US-based biotech investors over China's ascent
Some VCs are capitalizing on China's rise by licensing in molecules and forming NewCo's.
Others, like Curie Bio's Zach Weinberg, see a threat to the US biotech industry:
endpoints.news/us-investors...
Some VCs are capitalizing on China's rise by licensing in molecules and forming NewCo's.
Others, like Curie Bio's Zach Weinberg, see a threat to the US biotech industry:
endpoints.news/us-investors...
China’s rise splits US biotech investors: Cash in, or counter?
US investors debate response to China's rise in drug development, with some seeing a national security threat while others embrace collaboration. FDA and policymakers consider reforms to maintain comp...
endpoints.news
July 2, 2025 at 3:11 PM
NEW: An inside look at the growing divide among US-based biotech investors over China's ascent
Some VCs are capitalizing on China's rise by licensing in molecules and forming NewCo's.
Others, like Curie Bio's Zach Weinberg, see a threat to the US biotech industry:
endpoints.news/us-investors...
Some VCs are capitalizing on China's rise by licensing in molecules and forming NewCo's.
Others, like Curie Bio's Zach Weinberg, see a threat to the US biotech industry:
endpoints.news/us-investors...
NEW: Some expert reaction & further context around FDA head Marty Makary's unsuccessful attempt to intervene in KalVista's drug review:
endpoints.news/fda-head-mak...
endpoints.news/fda-head-mak...
FDA head Makary’s short-lived CRL ask on KalVista’s drug raises more concerns of political intervention
FDA Commissioner Marty Makary’s unsuccessful attempt to intervene in an ongoing drug review, as described by multiple agency sources, raises further concerns about the regulator under its new leadersh...
endpoints.news
June 27, 2025 at 2:09 PM
NEW: Some expert reaction & further context around FDA head Marty Makary's unsuccessful attempt to intervene in KalVista's drug review:
endpoints.news/fda-head-mak...
endpoints.news/fda-head-mak...
Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say
endpoints.news/sources-fda-...
endpoints.news/sources-fda-...
Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say
FDA Commissioner Marty Makary reportedly attempted to reject KalVista Pharmaceuticals' drug application, sources said. An HHS spokesperson calls the claim 'totally false.'
endpoints.news
June 24, 2025 at 5:36 PM
Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say
endpoints.news/sources-fda-...
endpoints.news/sources-fda-...
Basecamp CEO Glen Glowers on a "data wall" in AI bio:
“These foundation models are simply at a point where they cannot grow anymore. We’ve effectively run out of the internet in biology."
BaseData is like "being able to grow more internet for biology," Gowers says: endpoints.news/basecamp-res...
“These foundation models are simply at a point where they cannot grow anymore. We’ve effectively run out of the internet in biology."
BaseData is like "being able to grow more internet for biology," Gowers says: endpoints.news/basecamp-res...
Basecamp pitches a fix for AI bio's 'data wall'
Basecamp Research's global expeditions built BaseData, containing 9.8B protein sequences - 10x larger than public datasets - to advance AI biology models with Nvidia
endpoints.news
June 11, 2025 at 12:00 PM
Basecamp CEO Glen Glowers on a "data wall" in AI bio:
“These foundation models are simply at a point where they cannot grow anymore. We’ve effectively run out of the internet in biology."
BaseData is like "being able to grow more internet for biology," Gowers says: endpoints.news/basecamp-res...
“These foundation models are simply at a point where they cannot grow anymore. We’ve effectively run out of the internet in biology."
BaseData is like "being able to grow more internet for biology," Gowers says: endpoints.news/basecamp-res...
Here's a must-read deep dive into Bexorg, a biotech restoring dead human brains for better drug testing.
A wild one from New Haven, CT from @scienceboss.bsky.social : endpoints.news/rebooting-de...
A wild one from New Haven, CT from @scienceboss.bsky.social : endpoints.news/rebooting-de...
Exclusive: Rebooting dead human brains, a biotech startup seeks to reinvent early drug testing work
Startup Bexorg, led by Zvonimir Vrselja, keeps human brains alive to test drugs. Their BrainEx system sustains brain cells for 24 hours to improve drug development and reduce animal testing.
endpoints.news
June 10, 2025 at 3:36 PM
Here's a must-read deep dive into Bexorg, a biotech restoring dead human brains for better drug testing.
A wild one from New Haven, CT from @scienceboss.bsky.social : endpoints.news/rebooting-de...
A wild one from New Haven, CT from @scienceboss.bsky.social : endpoints.news/rebooting-de...
NEW: Recursion is laying off 20% of its workforce, likely cutting over 150 jobs, @kylelahucik.bsky.social reports
Recursion, a first generation AI-focused biotech, cut its pipeline nearly in half last month, shelving five clinical- or near-clinical-stage programs
endpoints.news/recursion-to...
Recursion, a first generation AI-focused biotech, cut its pipeline nearly in half last month, shelving five clinical- or near-clinical-stage programs
endpoints.news/recursion-to...
Recursion to lay off 20% of staff, a month after slashing its pipeline
The Salt Lake City-based biotech disclosed the job cuts in an SEC filing on Tuesday morning. More than 150 employees are likely being let go.
endpoints.news
June 10, 2025 at 12:34 PM
NEW: Recursion is laying off 20% of its workforce, likely cutting over 150 jobs, @kylelahucik.bsky.social reports
Recursion, a first generation AI-focused biotech, cut its pipeline nearly in half last month, shelving five clinical- or near-clinical-stage programs
endpoints.news/recursion-to...
Recursion, a first generation AI-focused biotech, cut its pipeline nearly in half last month, shelving five clinical- or near-clinical-stage programs
endpoints.news/recursion-to...
NEW: A trio of young MIT scientists say their new AI model has made progress in predicting binding affinity, a key property in drug discovery
Good affinity prediction has evaded other AI models, but Boltz-2 showed solid improvement:
endpoints.news/mit-scientis...
Good affinity prediction has evaded other AI models, but Boltz-2 showed solid improvement:
endpoints.news/mit-scientis...
MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D
MIT scientists unveil Boltz-2, a new AI model predicting drug binding affinities. Led by Gabriele Corso, Saro Passaro & Jeremy Wohlwend, it outperforms previous AI methods in drug discovery.
endpoints.news
June 6, 2025 at 1:49 PM
NEW: A trio of young MIT scientists say their new AI model has made progress in predicting binding affinity, a key property in drug discovery
Good affinity prediction has evaded other AI models, but Boltz-2 showed solid improvement:
endpoints.news/mit-scientis...
Good affinity prediction has evaded other AI models, but Boltz-2 showed solid improvement:
endpoints.news/mit-scientis...
Exclusive: Amplify Partners has raised $200 million for its first biotech-specific fund
Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups.
The Silicon Valley VC has also hired @elliothershberg.com as a partner: endpoints.news/amplify-rais...
Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups.
The Silicon Valley VC has also hired @elliothershberg.com as a partner: endpoints.news/amplify-rais...
Exclusive: Tech VC Amplify raises $200M for first biotech fund, hires Elliot Hershberg as new partner
The biotech fund — officially called Amplify Bio Fund I — plans to make about 20 investments exclusively in pre-seed, seed and Series A rounds.
endpoints.news
June 5, 2025 at 12:06 PM
Exclusive: Amplify Partners has raised $200 million for its first biotech-specific fund
Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups.
The Silicon Valley VC has also hired @elliothershberg.com as a partner: endpoints.news/amplify-rais...
Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups.
The Silicon Valley VC has also hired @elliothershberg.com as a partner: endpoints.news/amplify-rais...
Q&A: Sandoz CEO on the natural tension of generics vs. pharma, the coming generic GLP-1 experiment, Trump's tariffs, & more:
endpoints.news/qa-sandoz-ce...
endpoints.news/qa-sandoz-ce...
Q&A: Sandoz CEO Richard Saynor on generic GLP-1s, Trump's industry impact, and Mark Cuban's company
Richard Saynor discusses his 35-year career in generics, Sandoz's 80% stock rise since the Novartis spinoff, and views on drug pricing and FDA changes.
endpoints.news
June 3, 2025 at 12:02 PM
Q&A: Sandoz CEO on the natural tension of generics vs. pharma, the coming generic GLP-1 experiment, Trump's tariffs, & more:
endpoints.news/qa-sandoz-ce...
endpoints.news/qa-sandoz-ce...
Exclusive: ProteinQure has raised an $11 million Series A, planning to enter the clinic later this year with its first drug candidate: a peptide-drug conjugate for triple-negative breast cancer
endpts.com/exclusive-pr...
endpts.com/exclusive-pr...
Exclusive: Toronto biotech ProteinQure nears the clinic with peptide platform as it raises $11M Series A
ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast cancer, into clinical trials by Q3, pivoting from quantum to AI.
endpts.com
May 27, 2025 at 12:29 PM
Exclusive: ProteinQure has raised an $11 million Series A, planning to enter the clinic later this year with its first drug candidate: a peptide-drug conjugate for triple-negative breast cancer
endpts.com/exclusive-pr...
endpts.com/exclusive-pr...
Post-Hoc: AI's CRISPR moment
Both technologies are powerful and hold vast potential. But the AI bio field should learn lessons from the overhyped history of CRISPR in how its leaders set expectations:
endpts.com/post-hoc-ai-...
Both technologies are powerful and hold vast potential. But the AI bio field should learn lessons from the overhyped history of CRISPR in how its leaders set expectations:
endpts.com/post-hoc-ai-...
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, responding to DeepMind CEO's disease cure claims.
endpts.com
May 22, 2025 at 11:43 AM
Post-Hoc: AI's CRISPR moment
Both technologies are powerful and hold vast potential. But the AI bio field should learn lessons from the overhyped history of CRISPR in how its leaders set expectations:
endpts.com/post-hoc-ai-...
Both technologies are powerful and hold vast potential. But the AI bio field should learn lessons from the overhyped history of CRISPR in how its leaders set expectations:
endpts.com/post-hoc-ai-...
NEW: I dove into the precarious state of biotech's real-estate market
Companies like Ginkgo, Prime, and Boundless Bio face some of the largest relative lease burdens, weighing down their balance sheets for years to come.
My latest for @endpts.com
endpts.com/biotech-down...
Companies like Ginkgo, Prime, and Boundless Bio face some of the largest relative lease burdens, weighing down their balance sheets for years to come.
My latest for @endpts.com
endpts.com/biotech-down...
Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability
Biotech companies face financial strain from expensive long-term leases signed during pandemic boom, with Ginkgo Bioworks, Prime Medicine & others struggling with high lease obligations amid market do...
endpts.com
May 21, 2025 at 3:05 PM
NEW: I dove into the precarious state of biotech's real-estate market
Companies like Ginkgo, Prime, and Boundless Bio face some of the largest relative lease burdens, weighing down their balance sheets for years to come.
My latest for @endpts.com
endpts.com/biotech-down...
Companies like Ginkgo, Prime, and Boundless Bio face some of the largest relative lease burdens, weighing down their balance sheets for years to come.
My latest for @endpts.com
endpts.com/biotech-down...
EXCLUSIVE: Datavant has agreed to acquire Aetion in a deal doubling the size of Datavant's life sciences team
The two healthcare data specialists will officially announce the deal later this morning.
Read it at @endpts.com first: endpts.com/exclusive-da...
The two healthcare data specialists will officially announce the deal later this morning.
Read it at @endpts.com first: endpts.com/exclusive-da...
Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team
Datavant acquires Aetion in health data merger. Deal doubles life sciences team to 400. CEO Kyle Armbrester says company has $1B+ revenue. Terms undisclosed. More M&A expected.
endpts.com
May 15, 2025 at 12:32 PM
EXCLUSIVE: Datavant has agreed to acquire Aetion in a deal doubling the size of Datavant's life sciences team
The two healthcare data specialists will officially announce the deal later this morning.
Read it at @endpts.com first: endpts.com/exclusive-da...
The two healthcare data specialists will officially announce the deal later this morning.
Read it at @endpts.com first: endpts.com/exclusive-da...
NEW: Recursion is abandoning or pausing 5 drug programs, cutting nearly half its pipeline — including what were its most clinically advanced efforts
Recursion's stock is down 10% this morning
Details: endpts.com/ai-biotech-r...
Recursion's stock is down 10% this morning
Details: endpts.com/ai-biotech-r...
Recursion cuts nearly half of its pipeline, including its most advanced program
Recursion has cut five drug programs as CEO Chris Gibson focuses on 'winners' in its pipeline.
endpts.com
May 5, 2025 at 3:23 PM
NEW: Recursion is abandoning or pausing 5 drug programs, cutting nearly half its pipeline — including what were its most clinically advanced efforts
Recursion's stock is down 10% this morning
Details: endpts.com/ai-biotech-r...
Recursion's stock is down 10% this morning
Details: endpts.com/ai-biotech-r...
“Anybody can spin up big dreams about what might be possible with AI and then get dinged for hype,” Iambic CEO Tom Miller told me. “We really like to lean into what we’ve actually done.”
More here in my @endpts.com latest: endpts.com/ai-biotech-i...
More here in my @endpts.com latest: endpts.com/ai-biotech-i...
Iambic debuts next version of AI model Enchant, driving new way for drug R&D
Iambic Therapeutics enhances AI model Enchant v2 with 10x more training data, improving drug property predictions.
endpts.com
May 5, 2025 at 1:35 PM
“Anybody can spin up big dreams about what might be possible with AI and then get dinged for hype,” Iambic CEO Tom Miller told me. “We really like to lean into what we’ve actually done.”
More here in my @endpts.com latest: endpts.com/ai-biotech-i...
More here in my @endpts.com latest: endpts.com/ai-biotech-i...